Showing results (11-20 of 41) with videos related to
Sort By:
Pageof 5
Frontiers in Oncology|March 29, 2021
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase InhibitorsElizabeth Dudnik, Jair Bar, Assaf Moore, et al.Clinical Lung Cancer|January 17, 2022
dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50Liran Holtzman, Mor Moskovitz, Damien Urban, et al.International Journal of Cancer|September 3, 2020
Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real-world evidenceElizabeth Dudnik, Mor Moskovitz, Abed Agbarya, et al.Oncoimmunology|February 8, 2021
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, et al.International Journal of Radiation Oncology, Biology, Physics|November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter StudyItamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.The Lancet. Oncology|September 11, 2025
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b studyKelly G Paulson, Sally C M Lau, Myung-Ju Ahn, et al.Journal for Immunotherapy of Cancer|February 18, 2021
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungElizabeth Dudnik, Samuel Kareff, Mor Moskovitz, et al.Expert Review of Anticancer Therapy|July 1, 2024
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLCPierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, et al.Cancers|September 3, 2020
Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical OutcomeGil Bar-Sela, Idan Cohen, Salvatore Campisi-Pinto, et al.Journal of Neuro-Oncology|February 7, 2024
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatmentItamar Averbuch, Roi Tschernichovsky, Shlomit Yust-Katz, et al.Pageof 5